---
title: "ADIL.US (ADIL.US) — Related News"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/ADIL.US/news.md"
symbol: "ADIL.US"
name: "ADIL.US"
parent: "https://longbridge.com/en/quote/ADIL.US.md"
datetime: "2026-05-21T14:40:41.615Z"
locales:
  - [en](https://longbridge.com/en/quote/ADIL.US/news.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/ADIL.US/news.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/ADIL.US/news.md)
---

# ADIL.US (ADIL.US) — Related News

### [Pre-market hot trades in US stocks: Xanadu Quantum Tech - B up 8.65% in pre-market; Adial Pharmaceuticals down 7.07% in pre-market](https://longbridge.com/en/news/287199018.md)
*2026-05-21T10:17:22.000Z*
> Xanadu Quantum Tech - B pre-market up 8.65%; Adial Pharmaceuticals pre-market down 7.07%; Wheeler Real Estate pre-market

### [MTVA Gains Weight, CODX Takes A Shot At Ebola, EDSA To Reveal New Data, BDTX On Watch](https://longbridge.com/en/news/287035625.md)
*2026-05-20T09:04:22.000Z*
> In Tuesday's trading, biotech stocks saw significant gains. MetaVia Inc. (MTVA) surged over 69% as it advances its obesi

### [Adial Pharmaceuticals: Buy Rating Reiterated as AD04’s Precision AUD Strategy Advances; $8 Price Target Maintained](https://longbridge.com/en/news/286301632.md)
*2026-05-13T18:15:19.000Z*
> Analyst Jason McCarthy of Maxim Group has reiterated a Buy rating on Adial Pharmaceuticals, maintaining an $8 price targ

### [ADIA Nutrition Announces IRB Approval of All Four Clinical Studies and Registration of Kidney Health Study on ClinicalTrials.gov | ADIA Stock News](https://longbridge.com/en/news/285957760.md)
*2026-05-11T06:05:32.000Z*
> ADIA Nutrition Announces IRB Approval of All Four Clinical Studies and Registration of Kidney Health Study on ClinicalTr

### [Adial Pharma’s Strategic Options: High-Stakes Search for a Deal Puts Share Price and Long-Term Prospects at Risk](https://longbridge.com/en/news/285831470.md)
*2026-05-10T06:01:02.000Z*
> Adial Pharma (ADIL) is exploring strategic alternatives, including mergers and asset sales, but faces risks that any dea

### [00:00 ETAlebund Pharmaceuticals Announces Completion of Patient Enrollment in Global Phase III Pivotal Multi-Regional Clinical Trial of AP301 for Hyperphosphatemia](https://longbridge.com/en/news/285307826.md)
*2026-05-06T04:02:18.000Z*
> Alebund Pharmaceuticals has completed patient enrollment in its global Phase III clinical trial for AP301, a novel treat

### [Adial Pharmaceuticals Advances IP Portfolio with New U.S. Utility Patent Application, Positioning for Potential Market Exclusivity Through 2045 | ADIL Stock News](https://longbridge.com/en/news/284581655.md)
*2026-04-29T05:07:00.000Z*
> Adial Pharmaceuticals has filed a new U.S. utility patent application for its lead investigational drug, AD04, aimed at 

### [Adial Pharmaceuticals Submits Application to FDA Commissioner’s National Priority Voucher (CNPV) Pilot Program for AD04 Clinical Development Program | ADIL Stock News](https://longbridge.com/en/news/284219502.md)
*2026-04-27T04:50:44.000Z*
> Adial Pharmaceuticals Submits Application to FDA Commissioner’s National Priority Voucher (CNPV) Pilot Program for AD04